Anti-IFNAR1 drug administration plan for subcutaneous injection

Optimal subcutaneous doses of aniflorumab, identified through data modeling, address the inconvenience of intravenous administration in SLE treatment, achieving equivalent efficacy and improving clinical outcomes.

JP2026086416APending Publication Date: 2026-05-26ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026003230
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-28
Filing Date
2026-01-13
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Current treatments for systemic lupus erythematosus (SLE) are inconvenient for patients due to intravenous administration requirements, and there is a need for a safe and effective subcutaneous dose of aniflorumab, a type I IFN receptor (IFNAR1) inhibitor, as predicting PK and efficacy is difficult.

Method used

Identifying optimal subcutaneous doses of aniflorumab through innovative data modeling, ensuring safety and efficacy equivalent to intravenous administration, using unit doses between 105 mg and 150 mg for weekly administration.

Benefits of technology

Provides plasma concentrations equivalent to intravenous administration, reducing patient burden and improving BILAG-based composite lupus assessment and SLE Responder Index scores.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026086416000015
    Figure 2026086416000015
  • Figure 2026086416000016
    Figure 2026086416000016
  • Figure 2026086416000017
    Figure 2026086416000017
Patent Text Reader

Abstract

This invention provides a method and unit dose for the treatment of type I IFN-mediated diseases. [Solution] The present invention provides a unit dose for subcutaneous administration of a type I IFN receptor (IFNAR1) inhibitor in a dose greater than 105 mg (>) and less than 150 mg (<), specifically a human monoclonal antibody specific to IFNAR1, or optionally a modified IgG1 class human monoclonal antibody, and a method comprising subcutaneously administering the unit dose to a subject having a type I interferon (IFN)-mediated disease.
Need to check novelty before this filing date? Find Prior Art